News
FDA Inspection Surge Targets Compounded Semaglu...
FDA warning letters from March and April 2026 document specific impurity failures in compounded semaglutide, including N-acetyl semaglutide at 1.8%
FDA Inspection Surge Targets Compounded Semaglu...
FDA warning letters from March and April 2026 document specific impurity failures in compounded semaglutide, including N-acetyl semaglutide at 1.8%
FDA's Updated Guidance on Compounded Tirzepatid...
FDA's 2026 guidance tightens quality standards for compounded tirzepatide and semaglutide, mandating FDA-approved APIs, banning unapproved salt
FDA's Updated Guidance on Compounded Tirzepatid...
FDA's 2026 guidance tightens quality standards for compounded tirzepatide and semaglutide, mandating FDA-approved APIs, banning unapproved salt
Ozari Health's $86 Semaglutide and $125 Tirzepa...
Ozari Health advertises compounded semaglutide for $86 and tirzepatide for $125, but new 2026 GLP-1 data and FDA enforcement actions reveal hidden
Ozari Health's $86 Semaglutide and $125 Tirzepa...
Ozari Health advertises compounded semaglutide for $86 and tirzepatide for $125, but new 2026 GLP-1 data and FDA enforcement actions reveal hidden
How FDA's Tirzepatide Quality Failures Could Tr...
FDA's subpotent tirzepatide findings are reshaping oversight. Here's how those quality failures could trigger targeted semaglutide inspections at
How FDA's Tirzepatide Quality Failures Could Tr...
FDA's subpotent tirzepatide findings are reshaping oversight. Here's how those quality failures could trigger targeted semaglutide inspections at
How FDA's New Draft Guidance Could Reshape Comp...
FDA's new draft guidance excludes tirzepatide and semaglutide from bulk compounding, potentially ending most compounded GLP-1 access. Here's what
How FDA's New Draft Guidance Could Reshape Comp...
FDA's new draft guidance excludes tirzepatide and semaglutide from bulk compounding, potentially ending most compounded GLP-1 access. Here's what
FTC Warning Letters on Compounded GLP-1 Ads: Wh...
FTC warning letters target compounded tirzepatide and semaglutide ads that omit prescription status or imply FDA approval. Sellers face fines up to
FTC Warning Letters on Compounded GLP-1 Ads: Wh...
FTC warning letters target compounded tirzepatide and semaglutide ads that omit prescription status or imply FDA approval. Sellers face fines up to